A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results